title: Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the United States, 2000-2010.
abstract: We assessed laboratory monitoring after combination antiretroviral therapy initiation among 3678 patients in a large US multisite clinical cohort, censoring participants at last clinic visit, combination antiretroviral therapy change, or 3 years. Median days (interquartile range) to first hematologic, hepatic, renal, and lipid tests were 30 (18-53), 31 (19-56), 33 (20-59), and 350 (96-1106), respectively. At 1 year, approximately 80% received more than 2 hematologic, hepatic, and renal tests consistent with guidelines. However, only 40% received 1 or more lipid tests. Monitoring was more frequent in specific subgroups, likely reflecting better clinic attendance or clinician perception of higher susceptibility to toxicities.
authors: Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27517, USA. elizabeth_yanik@med.unc.edu
authors: Elizabeth L
authors: EL
authors: Yanik
authors: Sonia
authors: S
authors: Napravnik
authors: Patrick
authors: P
authors: Ryscavage
authors: Joseph J
authors: JJ
authors: Eron
authors: Susan L
authors: SL
authors: Koletar
authors: Richard D
authors: RD
authors: Moore
authors: Anne
authors: A
authors: Zinski
authors: Stephen R
authors: SR
authors: Cole
authors: Peter
authors: P
authors: Hunt
authors: Heidi M
authors: HM
authors: Crane
authors: James
authors: J
authors: Kahn
authors: William C
authors: WC
authors: Mathews
authors: Kenneth H
authors: KH
authors: Mayer
authors: Babafemi O
authors: BO
authors: Taiwo
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001772:Blood Cell Count; D015331:Cohort Studies; D003404:Creatinine / Q000097:blood; D016903:Drug Monitoring; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D006403:Hematologic Tests; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D008055:Lipids / Q000097:blood*; D008099:Liver / Q000187:drug effects*; D008297:Male; D014481:United States
chemical_list: D019380:Anti-HIV Agents; D008055:Lipids; D003404:Creatinine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin